HRSA Debates Adding Rare MLD to Newborn Disease Screening Panel
Published Date: 8/14/2025
Notice
Summary
HRSA is thinking about adding Metachromatic Leukodystrophy (MLD), a serious condition, to the list of diseases newborns get screened for. This means babies could be tested early without families paying extra, helping catch MLD sooner and possibly save lives. HRSA wants your thoughts before making a final call, so speak up soon!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
If Added, Screening Covered Without Cost-Sharing
If HRSA adds Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP), newborn screening for MLD that is included in HRSA-supported comprehensive guidelines must be covered by non-grandfathered health plans without cost-sharing (no co-payment or co-insurance).
Supports Early Newborn Screening for MLD
HRSA is considering recommending MLD be added to the RUSP to support screening during the newborn period and is specifically asking for evidence about the potential benefit of early screening and the availability of effective treatments for MLD.
State Screening Capacity Will Be Considered
HRSA will consider the ability of state newborn screening programs to screen for MLD when deciding whether to recommend adding MLD to the RUSP, so state program capacity is part of the decision process.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in